James Panek
Director/Board Member at SUTRO BIOPHARMA, INC.
Net worth: - $ as of 2024-03-30
Profile
James P.
Panek is an Independent Director at Sutro Biopharma, Inc. and the Chief Operating Officer at CHO Plus, Inc. He previously served as the Chairman & Co-Chief Executive Officer at Celltrion, Inc. from 2002 to 2006.
From 2007 to 2011, he was the President, Chief Executive Officer, CFO & Director at Diadexus, Inc. Prior to that, he held the positions of President, Chief Financial Officer, CAO & Director at VaxGen, Inc. from 2002 to 2010.
He also served as a Director at diaDexus, Inc. and held the role of Senior Vice President-Product Operations at Genentech, Inc. from 1982 to 2001.
Mr. Panek completed his undergraduate and graduate degrees at the University of Michigan.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SUTRO BIOPHARMA, INC.
-.--% | 2023-06-07 | 0 ( -.--% ) | - $ | 2024-03-30 |
James Panek active positions
| Companies | Position | Start |
|---|---|---|
| SUTRO BIOPHARMA, INC. | Director/Board Member | 2020-01-06 |
| Cho Plus, Inc. | Chief Operating Officer | - |
Former positions of James Panek
| Companies | Position | End |
|---|---|---|
| DIADEXUS, INC. | Chief Executive Officer | 2010-12-31 |
diaDexus, Inc. /Old/
 diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Director/Board Member | 2010-10-31 |
VaxGen, Inc.
 VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Director of Finance/CFO | 2009-12-31 |
| CELLTRION, INC. | Chief Executive Officer | 2005-12-31 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 2000-12-31 |
Training of James Panek
| University of Michigan | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SUTRO BIOPHARMA, INC. | Health Technology |
| CELLTRION, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
VaxGen, Inc.
VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Health Technology |
Diadexus, Inc.
 Diadexus, Inc. BiotechnologyHealth Technology Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
| Cho Plus, Inc. |
- Stock Market
- Insiders
- James Panek
